Literature DB >> 14755329

Achieving antigen-specific immune regulation.

Kevan C Herold1.   

Abstract

A study in this issue of the JCI shows that in response to autoantigens consisting of peptides from normal proteins, patients with diabetes mount a T cell response characterized by production of IFN-gamma (see the related article beginning on page 451). However, in response to these same antigens, T cells from normal control subjects produce IL-10. The antigen-specific response characterized by release of a regulatory cytokine suggests a mechanism for the control of autoimmunity that is initiated at the time of antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755329      PMCID: PMC324549          DOI: 10.1172/JCI20963

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

Review 1.  Suppressor T cells--they're back and critical for regulation of autoimmunity!

Authors:  L Chatenoud; B Salomon; J A Bluestone
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

Review 2.  Regulatory T cells in autoimmmunity*.

Authors:  E M Shevach
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 3.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

4.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

5.  Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.

Authors:  E Hyppönen; E Läärä; A Reunanen; M R Järvelin; S M Virtanen
Journal:  Lancet       Date:  2001-11-03       Impact factor: 79.321

6.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Authors:  Kevan C Herold; Joshua B Burton; Fleur Francois; Ena Poumian-Ruiz; Mariela Glandt; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 7.  An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus.

Authors:  A Rabinovitch
Journal:  Diabetes Metab Rev       Date:  1998-06

8.  Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV.

Authors:  Shahram Salek-Ardakani; John R Arrand; Mike Mackett
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616

9.  IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells.

Authors:  M K Levings; R Sangregorio; F Galbiati; S Squadrone; R de Waal Malefyt; M G Roncarolo
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

10.  In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.

Authors:  Franck J Barrat; Daniel J Cua; André Boonstra; David F Richards; Chad Crain; Huub F Savelkoul; René de Waal-Malefyt; Robert L Coffman; Catherine M Hawrylowicz; Anne O'Garra
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

View more
  9 in total

1.  Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo.

Authors:  Yen-Tung A Teng; Deeqa Mahamed; Bhagirath Singh
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 2.  Regulatory T cells and type 1 diabetes.

Authors:  Brygida C Bisikirska; Kevan C Herold
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

3.  Interleukin-10 inhibits gram-negative-microbe-specific human receptor activator of NF-kappaB ligand-positive CD4+-Th1-cell-associated alveolar bone loss in vivo.

Authors:  Xiaoxia Zhang; Yen-Tung A Teng
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 4.  Teplizumab therapy for type 1 diabetes.

Authors:  Umesh B Masharani; Joseph Becker
Journal:  Expert Opin Biol Ther       Date:  2010-03       Impact factor: 4.388

Review 5.  Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.

Authors:  Mariela Glandt; Kevan C Herold
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

6.  Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children.

Authors:  C-O Jonson; M Pihl; C Nyholm; C M Cilio; J Ludvigsson; M Faresjö
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

7.  Activation of the transcriptional function of the NF-κB protein c-Rel by O-GlcNAc glycosylation.

Authors:  Parameswaran Ramakrishnan; Peter M Clark; Daniel E Mason; Eric C Peters; Linda C Hsieh-Wilson; David Baltimore
Journal:  Sci Signal       Date:  2013-08-27       Impact factor: 8.192

Review 8.  New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.

Authors:  S Cernea; P Pozzilli
Journal:  Diabet Med       Date:  2008-11       Impact factor: 4.359

9.  Effects of recombinant human interleukin-10 on Treg cells, IL-10 and TGF-β in transplantation of rabbit skin.

Authors:  Kai Shan Liu; Xiao Qin Fan; Lei Zhang; Qiong Na Wen; Ji Hong Feng; Fu Chao Chen; Jun Min Luo; Wan Bang Sun
Journal:  Mol Med Rep       Date:  2013-11-20       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.